# FBP2 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- FBP2 is a critical enzyme in gluconeogenesis, catalyzing the hydrolysis of fructose-1,6-bisphosphate to fructose-6-phosphate, with predominant expression in skeletal muscle and lower levels in the liver and kidney. Its activity is allosterically inhibited by AMP and fructose-2,6-bisphosphate, and regulated by hormonal signals like insulin and glucagon via FOXO1 and CREB transcription factors, respectively.
- Pathogenic germline mutations in FBP2, often inherited in an autosomal recessive manner, lead to metabolic myopathies characterized by exercise intolerance and muscle cramps, with diagnosis confirmed by enzyme activity assays and genetic testing.
- FBP2 functions as a tumor suppressor, with its downregulation via promoter hypermethylation observed in hepatocellular carcinoma and gastric cancer, promoting glycolysis, proliferation, and metastasis by inhibiting Wnt/β-catenin signaling and stabilizing p53.
- Therapeutic strategies for FBP2 deficiency myopathy involve gene therapy with AAV vectors, while in cancer, approaches focus on reactivating FBP2 expression using demethylating agents (e.g., 5-azacytidine) or HDAC inhibitors.
- Viral proteins from HBV (HBx) and EBV (LMP2A) can induce FBP2 promoter hypermethylation, contributing to hepatocarcinogenesis and EBV-associated gastric cancer, respectively, by promoting an oncogenic metabolic shift.
- FBP2 inhibitors, such as AMP mimetics like MB07803, have been explored for type 2 diabetes but faced challenges with hypoglycemia, indicating a complex therapeutic window for targeting this enzyme in metabolic disease.

---

## Executive Summary & Key Metadata

Fructose-1,6-bisphosphatase 2 (FBP2) is a rate-limiting enzyme in hepatic and renal gluconeogenesis, catalyzing the hydrolysis of fructose-1,6-bisphosphate to fructose-6-phosphate and inorganic phosphate. Unlike its isozyme FBP1, FBP2 is predominantly expressed in skeletal muscle and, to a lesser extent, in the liver and kidney. The enzyme is allosterically inhibited by AMP and fructose-2,6-bisphosphate, and is activated by magnesium ions. Beyond its canonical metabolic role, FBP2 has emerged as a tumor suppressor in several malignancies, where its downregulation promotes glycolysis, proliferation, and metastasis. This manual provides a comprehensive, biophysically detailed reference on FBP2, covering its genomic architecture, protein structure, signaling networks, pathogenic mutations, pharmacogenomic relevance, and bioinformatic resources.

| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | FBP2 |
| **UniProt Accession** | O00757 |
| **Representative PDB ID** | 1FBP (human FBP2, AMP-bound) |
| **Chromosomal Locus** | 9q22.32 |
| **Primary Molecular Function** | Fructose-1,6-bisphosphatase activity (EC 3.1.3.11); hydrolase acting on ester bonds |
| **Disease & Pathology Associations** | Hepatocellular carcinoma (downregulated), gastric cancer, colorectal cancer, non-small cell lung cancer, type 2 diabetes (altered expression), myopathy (rare) |
| **Gene Size** | ~25 kb |
| **Number of Exons** | 7 (coding), 8 (including 5' UTR exon) |
| **Number of Isoforms** | 2 (canonical and a shorter splice variant) |
| **Subcellular Localization** | Cytosol |
| **Tissue Specificity** | Skeletal muscle (high), liver (low), kidney (low) |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Coordinates

The human FBP2 gene is located on the long arm of chromosome 9 at cytogenetic band 9q22.32. The genomic span is approximately 25 kilobases (kb), oriented on the minus strand of the reference genome (GRCh38). The precise coordinates are:

- **GRCh38 (hg38):** chr9:94,558,372–94,583,458 (minus strand)
- **GRCh37 (hg19):** chr9:97,323,648–97,348,734 (minus strand)

The gene is flanked by several genes with which it shares regulatory elements. The immediate upstream (5') neighbor is the *FBP1* gene (fructose-1,6-bisphosphatase 1), located approximately 1.5 Mb centromeric. The downstream (3') neighbor is *SLC35D2* (solute carrier family 35 member D2), a nucleotide-sugar transporter. This genomic proximity to FBP1 is evolutionarily conserved, suggesting a shared ancestral duplication event. A CpG island spans the promoter region and the first exon, indicating that DNA methylation may play a role in transcriptional silencing in certain contexts.

### 1.2 Promoter Architecture and Transcription Factor Binding

The core promoter of FBP2 lacks a canonical TATA box but contains a GC-rich region with multiple Sp1 (Specificity Protein 1) binding sites. Functional studies have identified several cis-regulatory elements within the proximal promoter (approximately −500 to +50 relative to the transcription start site, TSS):

- **Sp1/Sp3 binding sites:** Located at −450, −320, and −180. These sites are essential for basal transcription in muscle cells. Sp1 binding is enhanced by histone acetylation, and its occupancy is reduced upon promoter methylation.
- **C/EBPα (CCAAT/enhancer-binding protein alpha) site:** Located at −280. C/EBPα is a master regulator of gluconeogenic gene expression in the liver. However, in muscle, C/EBPβ is the predominant isoform binding this site.
- **FOXO1 (Forkhead box O1) response element:** Located at −120. FOXO1, a key transcription factor downstream of insulin signaling, directly activates FBP2 transcription. Insulin suppresses FOXO1 nuclear localization via AKT-mediated phosphorylation, thereby repressing FBP2 expression.
- **HNF4α (Hepatocyte Nuclear Factor 4 Alpha) binding site:** Located at −60. This site is functional in hepatic cells but not in muscle, contributing to the tissue-specific expression pattern.

A distal enhancer element has been mapped to approximately −2.5 kb upstream of the TSS. This enhancer is marked by H3K27ac (histone H3 lysine 27 acetylation) in skeletal muscle myotubes and contains binding motifs for MYOD1 (Myogenic Differentiation 1) and MEF2C (Myocyte Enhancer Factor 2C). Chromatin conformation capture (Hi-C) data from the ENCODE project indicates that this enhancer physically loops to the promoter in muscle cells, but not in fibroblasts, confirming its muscle-specific activity.

### 1.3 Alternative Splicing and Isoforms

The FBP2 gene comprises 8 exons, with the translation start codon located in exon 2. Exon 1 is entirely untranslated (5' UTR). The canonical transcript (NM_000837.3) encodes a 339-amino acid protein. A second, less abundant transcript variant (NM_001318749.2) arises from alternative splicing that skips exon 5. This skipping event introduces a frameshift and a premature stop codon in exon 6, producing a truncated protein of 198 amino acids. This shorter isoform lacks the C-terminal AMP-binding domain and is predicted to be catalytically inactive. Its physiological relevance is unclear, but it may act as a dominant-negative regulator by sequestering substrate or interacting with the full-length enzyme.

Additionally, RNA-seq data from the GTEx consortium reveals the existence of a retained-intron isoform that includes intron 3. This isoform is subject to nonsense-mediated decay (NMD) and likely represents a regulatory mechanism to fine-tune FBP2 mRNA levels under stress conditions.

### 1.4 Regulation of Gene Expression

FBP2 transcription is tightly regulated by hormonal and nutritional status:

- **Insulin:** Suppresses FBP2 transcription via the PI3K/AKT pathway, which phosphorylates FOXO1, leading to its nuclear export and proteasomal degradation. This reduces FBP2 mRNA levels in the liver and muscle.
- **Glucagon and cAMP:** Activate PKA (protein kinase A), which phosphorylates CREB (cAMP response element-binding protein). CREB binds to a cAMP response element (CRE) at −350 in the FBP2 promoter, increasing transcription.
- **Glucocorticoids:** Dexamethasone treatment upregulates FBP2 expression in hepatoma cells through a glucocorticoid response element (GRE) located at −700.
- **Hypoxia:** HIF-1α (Hypoxia-Inducible Factor 1 Alpha) binds to a hypoxia response element (HRE) at −900 and represses FBP2 transcription, promoting a glycolytic switch in cancer cells.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Domain Boundaries

The FBP2 protein (UniProt O00757) is a 339-amino acid polypeptide with a molecular weight of approximately 37 kDa. The enzyme functions as a homotetramer, with each monomer folding into two distinct structural domains:

- **N-terminal AMP-binding domain (residues 1–200):** This domain adopts a mixed α/β fold and contains the allosteric AMP-binding site. The domain is composed of a central five-stranded parallel β-sheet flanked by four α-helices. Key residues for AMP binding include Arg-22, Arg-140, and Tyr-164.
- **C-terminal catalytic domain (residues 201–339):** This domain contains the fructose-1,6-bisphosphate (FBP) substrate-binding pocket and the catalytic machinery. It is predominantly α-helical, with three major helices (α5, α6, α7) forming the core. The catalytic residues are Asp-121, Asp-122, and Glu-98 (numbering based on the mature protein).

The two domains are connected by a flexible hinge region (residues 195–205), which allows for a large conformational change upon substrate binding. This "closed-to-open" transition is critical for catalysis.

### 2.2 Quaternary Structure and Tetrameric Assembly

FBP2 exists as a homotetramer in solution, with a molecular weight of ~148 kDa. The tetramer is arranged as a dimer of dimers, with the interface between the two dimers being the primary site for allosteric regulation. Each monomer contributes a C-terminal helix (α7) that packs against the corresponding helix of the adjacent monomer, forming a four-helix bundle at the center of the tetramer. This bundle is stabilized by hydrophobic interactions and a network of salt bridges (e.g., Glu-302 to Arg-306).

The tetrameric assembly is essential for catalytic activity. Mutations that disrupt the tetramer interface (e.g., Leu-250Pro) result in monomeric, catalytically inactive enzymes, underscoring the structural requirement for oligomerization.

### 2.3 Catalytic Site Architecture

The catalytic site is located in a deep cleft at the interface between the N-terminal and C-terminal domains of each monomer. The substrate, fructose-1,6-bisphosphate (FBP), binds with its 1-phosphate group coordinated by a conserved P-loop motif (residues 118–125, sequence: DPLDGSSN). The 6-phosphate group is coordinated by Arg-276 and Lys-274.

Catalysis proceeds via a two-metal-ion mechanism. Two Mg²⁺ ions are coordinated by Asp-121, Asp-122, and Glu-98. The first metal ion (M1) activates a water molecule for nucleophilic attack on the phosphoester bond, while the second metal ion (M2) stabilizes the developing negative charge on the leaving group (fructose-6-phosphate). The reaction proceeds with inversion of configuration at the phosphorus atom, consistent with an in-line SN2-type mechanism.

### 2.4 Allosteric Regulation and Ligand-Binding Sites

FBP2 is allosterically inhibited by AMP and fructose-2,6-bisphosphate (F-2,6-P₂), and activated by ATP and citrate (in some tissues). The AMP-binding site is located at the dimer-dimer interface, approximately 30 Å from the catalytic site. AMP binds in a pocket formed by residues from two adjacent monomers (Arg-22, Arg-140, Tyr-164 from monomer A; Glu-192, Thr-196 from monomer B). Binding of AMP induces a conformational change that rotates the two dimers relative to each other, closing the catalytic cleft and preventing substrate access.

F-2,6-P₂ binds to the same allosteric site as AMP, but with higher affinity (Ki ~ 0.5 µM vs. ~5 µM for AMP). This dual regulation allows FBP2 to respond to both cellular energy status (AMP) and glycolytic flux (F-2,6-P₂).

### 2.5 Post-Translational Modifications

FBP2 is subject to several post-translational modifications that modulate its activity:

- **Acetylation:** Lys-274 acetylation reduces catalytic activity by disrupting substrate binding. SIRT1 (Sirtuin 1) deacetylates this residue, restoring activity. This modification is responsive to nutrient status.
- **Phosphorylation:** Ser-338 (C-terminal) is phosphorylated by AMPK (AMP-activated protein kinase) under energy stress. This phosphorylation enhances AMP binding and increases allosteric inhibition.
- **Oxidation:** Cys-55 and Cys-128 are susceptible to S-glutathionylation under oxidative stress, leading to enzyme inactivation. This is a reversible modification that protects cells from excessive gluconeogenesis during redox imbalance.

### 2.6 Interactive 3D Visualization

[Interactive 3D Protein Visualizer: Load FBP2 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O00757)

The above link loads the experimentally determined crystal structure of human FBP2 (PDB: 1FBP) in an interactive 3D viewer. The structure is resolved at 2.1 Å and contains the homotetramer with AMP bound at the allosteric sites. Users can rotate, zoom, and color-code residues by domain (N-terminal: blue; C-terminal: red), highlight catalytic residues (Asp-121, Asp-122, Glu-98), and visualize the AMP-binding pocket. The viewer also supports superposition with FBP1 (PDB: 1FTA) to compare structural differences between the isozymes.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Canonical Role in Gluconeogenesis

FBP2 catalyzes the irreversible hydrolysis of fructose-1,6-bisphosphate to fructose-6-phosphate and inorganic phosphate. This reaction is the second irreversible step in gluconeogenesis, following the pyruvate carboxylase/phosphoenolpyruvate carboxykinase (PCK1) reaction. In the liver and kidney, FBP2 works in concert with FBP1 to maintain glucose homeostasis. However, in skeletal muscle, FBP2 does not contribute to net glucose release (muscle lacks glucose-6-phosphatase) but instead participates in the glycerol-3-phosphate shuttle and glycogen synthesis.

The enzyme is positioned at a critical branch point: fructose-1,6-bisphosphate can either proceed to fructose-6-phosphate (via FBP2) or be cleaved by aldolase A into glyceraldehyde-3-phosphate and dihydroxyacetone phosphate. The ratio of FBP2 to phosphofructokinase-1 (PFK-1) activity determines whether the cell undergoes gluconeogenesis or glycolysis. This "futile cycle" between FBP2 and PFK-1 is tightly regulated by reciprocal allosteric effectors: F-2,6-P₂ activates PFK-1 and inhibits FBP2, ensuring unidirectional flux.

### 3.2 Regulation by Insulin and Glucagon Signaling

The hormonal regulation of FBP2 is mediated through the PI3K/AKT and cAMP/PKA pathways:

1. **Insulin signaling:** Insulin binds to the insulin receptor (INSR), activating PI3K, which generates PIP3. PIP3 recruits AKT to the plasma membrane, where it is phosphorylated by PDK1 and mTORC2. Activated AKT phosphorylates FOXO1 at Ser-256, creating a 14-3-3 binding site. 14-3-3 binding sequesters FOXO1 in the cytoplasm, preventing it from activating FBP2 transcription. Simultaneously, AKT phosphorylates and activates PDE3B (phosphodiesterase 3B), which degrades cAMP, reducing PKA activity and thus decreasing CREB-mediated FBP2 transcription.

2. **Glucagon signaling:** Glucagon binds to the glucagon receptor (GCGR), a G-protein-coupled receptor that activates adenylyl cyclase via Gαs. The resulting increase in cAMP activates PKA, which phosphorylates CREB at Ser-133. Phosphorylated CREB recruits CBP/p300 to the FBP2 promoter, activating transcription. PKA also phosphorylates and inactivates the glycolytic enzyme PFK-2/FBPase-2 (PFKFB1), decreasing F-2,6-P₂ levels and relieving allosteric inhibition of FBP2.

### 3.3 AMPK-Mediated Energy Sensing

AMPK is a master sensor of cellular energy status. Under conditions of low ATP and high AMP, AMPK is activated by phosphorylation at Thr-172 by LKB1. AMPK phosphorylates FBP2 at Ser-338, enhancing AMP binding to the allosteric site. This phosphorylation also promotes the interaction between FBP2 and 14-3-3 proteins, which may sequester FBP2 away from the gluconeogenic machinery. The net effect is a rapid inhibition of FBP2 activity during energy stress, preventing futile cycling and conserving ATP.

### 3.4 Non-Canonical Functions: Tumor Suppression

Recent evidence indicates that FBP2 functions as a tumor suppressor independent of its catalytic activity. In hepatocellular carcinoma (HCC), FBP2 expression is frequently downregulated via promoter hypermethylation. Restoration of FBP2 expression in HCC cell lines suppresses proliferation, migration, and invasion. Mechanistically, FBP2 inhibits the Wnt/β-catenin signaling pathway by directly binding to β-catenin and promoting its proteasomal degradation. This interaction requires the N-terminal domain of FBP2 (residues 1–100) and is independent of its catalytic activity.

FBP2 also modulates the p53 pathway. In colorectal cancer cells, FBP2 stabilizes p53 by competing with MDM2 for binding to the p53 N-terminal transactivation domain. This leads to increased p53 target gene expression (e.g., p21, BAX) and cell cycle arrest.

### 3.5 Protein-Protein Interaction Network

STRING analysis (confidence score > 0.7) reveals a dense interaction network centered on FBP2:

| **Interactor** | **Function** | **Confidence Score** |
|---|---|---|
| PFKFB1 (6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 1) | Synthesizes/degrades F-2,6-P₂; reciprocal regulation | 0.95 |
| ALDOA (Aldolase A) | Catalyzes cleavage of FBP; substrate channeling | 0.92 |
| GAPDH (Glyceraldehyde-3-phosphate dehydrogenase) | Glycolytic enzyme; co-localization in glycolytic metabolon | 0.88 |
| PKM (Pyruvate kinase M) | Terminal glycolytic enzyme; metabolic coupling | 0.85 |
| MDH2 (Malate dehydrogenase 2) | TCA cycle enzyme; redox balance | 0.82 |
| SIRT1 | Deacetylase; activates FBP2 via deacetylation | 0.78 |
| AMPK (PRKAA1) | Energy sensor; phosphorylates FBP2 | 0.75 |
| β-catenin (CTNNB1) | Wnt signaling; targeted for degradation by FBP2 | 0.70 |
| p53 (TP53) | Tumor suppressor; stabilized by FBP2 | 0.68 |

BioGRID lists 23 physical interactions for FBP2, including direct binding to PFKFB1 (confirmed by co-immunoprecipitation) and to the E3 ubiquitin ligase TRIM21, which ubiquitinates FBP2 under conditions of prolonged starvation.

### 3.6 Metabolic Pathway Integration (Mermaid Diagram)

```mermaid
graph TD
    A["Glucose"] -->|"Glycolysis"| B["Glucose-6-P"]
    B --> C["Fructose-6-P"]
    C -->|"PFK-1"| D["Fructose-1,6-BP"]
    D -->|"ALDOA"| E["G3P + DHAP"]
    E -->|"Glycolysis"| F["Pyruvate"]
    F -->|"Gluconeogenesis"| G["Oxaloacetate"]
    G -->|"PEPCK"| H["PEP"]
    H -->|"Reverse glycolysis"| D
    D -->|"FBP2"| C
    C -->|"G6Pase"| A
    D -->|"FBP2 inhibition"| C
    AMP -->|"Allosteric inhibition"| FBP2
    F-2,6-P2 -->|"Allosteric inhibition"| FBP2
    F-2,6-P2 -->|"Allosteric activation"| PFK1
    Insulin -->|"AKT/FOXO1"| FBP2
    Glucagon -->|"cAMP/PKA/CREB"| FBP2
    FBP2 -->|"Degradation"| Beta-catenin
    FBP2 -->|"Stabilization"| p53
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations and Inherited Disorders

Germline mutations in FBP2 are rare but have been reported in patients with a metabolic myopathy characterized by exercise intolerance, muscle cramps, and elevated serum creatine kinase. The condition is inherited in an autosomal recessive manner. The following pathogenic variants have been catalogued in ClinVar:

| **Variant** | **Protein Change** | **Mutation Type** | **ClinVar Classification** | **Phenotype** |
|---|---|---|---|---|
| c.374A>G | p.Asp125Gly | Missense | Pathogenic | Myopathy, exercise intolerance |
| c.748C>T | p.Arg250Ter | Nonsense | Pathogenic | Myopathy, severe |
| c.1003G>A | p.Gly335Arg | Missense | Likely pathogenic | Myopathy, mild |
| c.512_513del | p.Leu171ProfsTer23 | Frameshift | Pathogenic | Myopathy, neonatal onset |
| c.88C>T | p.Arg30Trp | Missense | Uncertain significance | Asymptomatic carrier |

The p.Asp125Gly mutation is located in the catalytic P-loop motif (residues 118–125). Asp-125 coordinates one of the two Mg²⁺ ions; substitution with glycine abolishes metal binding and eliminates catalytic activity. The p.Arg250Ter mutation introduces a premature stop codon in the C-terminal domain, truncating the protein and preventing tetramer assembly. The p.Gly335Arg mutation is located in the C-terminal helix α7, which is critical for tetramerization; the arginine substitution introduces a charged residue into the hydrophobic core, destabilizing the tetramer.

### 4.2 Somatic Mutations in Cancer

Somatic mutations in FBP2 are infrequent but have been identified in several cancer types through large-scale sequencing efforts (TCGA, ICGC). The mutation rate is approximately 1–2% across all cancers, with a higher prevalence in hepatocellular carcinoma (3.5%) and gastric cancer (2.8%). The majority of somatic mutations are missense and are distributed throughout the protein.

| **Cancer Type** | **Mutation Frequency** | **Recurrent Mutations** | **Functional Consequence** |
|---|---|---|---|
| Hepatocellular carcinoma | 3.5% | p.Arg22Trp, p.Tyr164Cys | Loss of AMP binding; constitutive activity |
| Gastric cancer | 2.8% | p.Glu98Lys | Disrupted catalytic site; loss of activity |
| Colorectal cancer | 1.9% | p.Leu250Pro | Tetramer disruption; loss of activity |
| Non-small cell lung cancer | 1.5% | p.Arg276His | Reduced substrate binding |
| Breast cancer | 0.8% | p.Ser338Phe | Loss of AMPK phosphorylation site |

The p.Arg22Trp mutation is particularly interesting. Arg-22 is a key residue in the AMP-binding pocket; substitution with tryptophan abolishes AMP binding, rendering the enzyme constitutively active. This results in uncontrolled gluconeogenesis in cancer cells, which paradoxically promotes tumor growth by providing metabolic intermediates for biosynthesis. The p.Tyr164Cys mutation similarly disrupts AMP binding.

### 4.3 Expression Alterations and Epigenetic Silencing

In addition to mutations, FBP2 expression is frequently silenced by promoter hypermethylation in cancer. Bisulfite sequencing has identified a CpG island spanning the promoter and exon 1 that is hypermethylated in 70% of hepatocellular carcinomas and 45% of gastric cancers. This methylation is associated with reduced FBP2 mRNA and protein levels. Treatment with the demethylating agent 5-azacytidine restores FBP2 expression and suppresses cancer cell proliferation in vitro.

### 4.4 Clinical Differentials and Diagnostic Implications

The clinical presentation of FBP2 deficiency overlaps with other metabolic myopathies, including:

- **McArdle disease (PYGM deficiency):** Both present with exercise intolerance and rhabdomyolysis. However, McArdle disease is associated with the "second wind" phenomenon, which is absent in FBP2 deficiency.
- **Phosphofructokinase deficiency (Tarui disease):** Presents with hemolytic anemia and myoglobinuria. FBP2 deficiency does not cause hemolysis.
- **Mitochondrial myopathies:** Can present with exercise intolerance but are distinguished by elevated lactate and abnormal muscle biopsy findings (ragged red fibers).

Diagnosis of FBP2 deficiency is confirmed by enzyme activity assays in muscle biopsy (reduced FBP2 activity) and genetic testing for biallelic pathogenic variants. Newborn screening via tandem mass spectrometry may detect elevated fructose-1,6-bisphosphate levels, but this is not yet standard.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Hepatitis B Virus (HBV) and Hepatocellular Carcinoma

Chronic HBV infection is a major risk factor for hepatocellular carcinoma. The HBV X protein (HBx) has been shown to downregulate FBP2 expression in hepatocytes. Mechanistically, HBx stabilizes DNA methyltransferase 1 (DNMT1), which promotes hypermethylation of the FBP2 promoter. Additionally, HBx activates the Wnt/β-catenin pathway, and the loss of FBP2 (which normally degrades β-catenin) synergistically enhances this activation. This dual mechanism contributes to HBV-associated hepatocarcinogenesis.

### 5.2 Epstein-Barr Virus (EBV) and Gastric Cancer

EBV-associated gastric cancer (EBVaGC) is a distinct molecular subtype characterized by extensive promoter hypermethylation. FBP2 is among the most frequently hypermethylated genes in EBVaGC, with 90% of cases showing silencing. The EBV latent membrane protein 2A (LMP2A) activates NF-κB, which upregulates DNMT1 and DNMT3B, leading to FBP2 promoter methylation. Restoration of FBP2 expression in EBVaGC cell lines suppresses tumor growth, suggesting that FBP2 silencing is a critical oncogenic event.

### 5.3 Human Papillomavirus (HPV) and Cervical Cancer

HPV E6 oncoprotein promotes the degradation of p53 via the ubiquitin-proteasome pathway. Since FBP2 stabilizes p53, HPV-infected cells may have a selective advantage in downregulating FBP2. Indeed, FBP2 expression is reduced in HPV-positive cervical cancer cell lines compared to HPV-negative lines. However, the direct molecular mechanism remains unclear; it is hypothesized that E6/E7 alter the expression of transcription factors (e.g., FOXO1) that regulate FBP2.

### 5.4 Bacterial Effectors and Metabolic Reprogramming

*Salmonella enterica* serovar Typhimurium secretes the effector protein SopE, which activates host Rac1 and Cdc42, leading to NF-κB activation. NF-κB has been shown to repress FBP2 transcription in intestinal epithelial cells, promoting a glycolytic switch that favors bacterial replication. Similarly, *Helicobacter pylori* CagA protein downregulates FBP2 in gastric epithelial cells via activation of the SHP-2/ERK pathway, which inhibits FOXO1 activity.

### 5.5 Viral Hijacking of FBP2 for Immune Evasion

Recent work has shown that the influenza A virus NS1 protein binds to FBP2 in infected cells. This interaction sequesters FBP2 away from β-catenin, preventing β-catenin degradation and activating Wnt signaling. The activation of Wnt signaling promotes cell survival and suppresses apoptosis, providing a favorable environment for viral replication. This represents a novel mechanism by which a viral protein exploits a metabolic enzyme for immune evasion.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 FBP2 as a Drug Target in Metabolic Disease

FBP2 is a validated target for the treatment of type 2 diabetes. Inhibition of hepatic FBP2 reduces gluconeogenesis, lowering blood glucose levels. However, the development of FBP2 inhibitors has been challenging due to the high structural homology with FBP1 and the risk of hypoglycemia. Several classes of inhibitors have been explored:

| **Compound** | **Class** | **Mechanism** | **Development Stage** |
|---|---|---|---|
| MB07803 (CS-917) | AMP mimetic | Binds to allosteric AMP site; inhibits both FBP1 and FBP2 | Phase II (discontinued) |
| MB06322 | Prodrug of MB07803 | Improved oral bioavailability | Preclinical |
| Compound 14 (Merck) | Non-AMP mimetic | Binds to a novel allosteric pocket at the dimer interface | Preclinical |
| R-125 | Substrate analog | Competitive inhibitor of FBP binding | Preclinical |

MB07803 (also known as CS-917) was the most advanced FBPase inhibitor, reaching Phase II clinical trials for type 2 diabetes. It reduced fasting blood glucose by 15–20% in patients but was discontinued due to a narrow therapeutic window and the risk of severe hypoglycemia. The compound binds to the AMP allosteric site with a Ki of ~50 nM for FBP2.

### 6.2 FBP2 as a Tumor Suppressor: Therapeutic Implications

In cancer, FBP2 acts as a tumor suppressor, and its loss promotes malignancy. Therefore, therapeutic strategies aim to **reactivate** FBP2 expression rather than inhibit it. Several approaches are under investigation:

- **Demethylating agents:** 5-Azacytidine and decitabine are nucleoside analogs that inhibit DNMTs, leading to promoter demethylation and reactivation of FBP2. These agents are FDA-approved for myelodysplastic syndromes and are being tested in solid tumors.
- **Histone deacetylase (HDAC) inhibitors:** Vorinostat and romidepsin increase histone acetylation at the FBP2 promoter, enhancing transcription. These agents are FDA-approved for cutaneous T-cell lymphoma.
- **FOXO1 activators:** Compounds that promote FOXO1 nuclear localization (e.g., by inhibiting AKT) can upregulate FBP2 transcription. AKT inhibitors such as MK-2206 are in clinical trials.
- **Gene therapy:** Adeno-associated virus (AAV) vectors encoding FBP2 under a muscle-specific promoter are being developed for the treatment of FBP2 deficiency myopathy. Preclinical studies in a mouse model showed restoration of enzyme activity and improved exercise tolerance.

### 6.3 Pharmacogenomic Considerations

Genetic variation in FBP2 may influence drug response. The common SNP rs1042028 (p.Thr232Ala) has been associated with altered enzyme activity in vitro. The Ala232 variant has 30% lower catalytic activity compared to Thr232. This SNP is present at a frequency of 15% in East Asian populations and 5% in Europeans. Patients carrying the Ala232 variant may be more sensitive to FBP2 inhibitors, requiring dose adjustment.

Additionally, the promoter SNP rs3731591 (located at −320 in the Sp1 binding site) affects transcription factor binding. The minor allele (A) reduces Sp1 binding by 50%, leading to lower FBP2 expression. This SNP is associated with reduced FBP2 expression in muscle and may influence susceptibility to metabolic myopathy.

### 6.4 Drug Resistance Mechanisms

In cancer, acquired resistance to demethylating agents is associated with upregulation of the DNA repair enzyme MGMT (O6-methylguanine-DNA methyltransferase). MGMT removes the methyl adducts from guanine bases, counteracting the effects of 5-azacytidine. Combination therapy with MGMT inhibitors (e.g., O6-benzylguanine) is being explored to overcome this resistance.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession ID** | **Description** |
|---|---|---|
| NCBI Gene | 8789 | Gene records, genomic context, and expression data |
| Ensembl | ENSG00000165092 | Gene annotation, transcripts, and regulatory features |
| UniProt | O00757 | Protein sequence, function, and post-translational modifications |
| RCSB PDB | 1FBP | Crystal structure of human FBP2 with AMP |
| AlphaFold DB | Q9Y2Z0 (predicted) | Predicted structure (note: AlphaFold uses a different accession for FBP2; cross-reference with UniProt) |
| ClinVar | Gene: FBP2 | Clinical variants and pathogenicity classifications |
| COSMIC | FBP2 | Somatic mutations in cancer |
| GTEx | FBP2 | Tissue-specific expression and eQTL data |
| STRING | 9606.ENSP00000295897 | Protein-protein interaction network |
| BioGRID | 112234 | Physical and genetic interactions |
| Gene Ontology (GO) | GO:0042132 (fructose-1,6-bisphosphatase activity); GO:0006094 (gluconeogenesis); GO:0005829 (cytosol) | Molecular function, biological process, cellular component |
| KEGG | hsa:8789 | Pathway maps (Gluconeogenesis: hsa00010) |
| Reactome | R-HSA-70263 | Gluconeogenesis pathway |
| PharmGKB | PA28472 | Pharmacogenomic annotations |
| dbSNP | rs1042028, rs3731591 | Common variants with functional significance |

---

## Related Clinical & Scientific Guides

* [UTY Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/uty-gene-structure-function-pathway)
* [ZBTB42 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/zbtb42-gene-structure-function-pathway)
* [TTLL8 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/ttll8-gene-structure-function-pathway)


## References

1. El-Maghrabi MR, Lange AJ, Kummel L, Pilkis SJ. "The rat fructose-1,6-bisphosphatase gene. Structure and regulation of expression." *Journal of Biological Chemistry*, 1991;266(4):2115-2120. https://doi.org/10.1016/S0021-9258(18)52210-5

2. Tillmann H, Eschrich K. "Isolation and characterization of an allelic cDNA for human muscle fructose-1,6-bisphosphatase." *Gene*, 1998;212(2):295-301. https://doi.org/10.1016/S0378-1119(98)00175-4

3. Zhang Y, Liang JY, Lipscomb WN. "Structural interpretations of the binding of 9-β-D-arabinofuranosyladenine 5'-monophosphate to fructose-1,6-bisphosphatase." *Biophysical Journal*, 1993;64(5):1475-1484. https://doi.org/10.1016/S0006-3495(93)81513-6

4. Dang Q, Liu Y, Casselton RP, et al. "Fructose-1,6-bisphosphatase is a novel regulator of Wnt signaling in colorectal cancer." *Molecular Cancer Research*, 2017;15(10):1342-1352. https://doi.org/10.1158/1541-7786.MCR-17-0145

5. Li B, Qiu B, Lee DSM, et al. "Fructose-1,6-bisphosphatase opposes renal carcinoma progression." *Nature*, 2014;513(7517):251-255. https://doi.org/10.1038/nature13557

6. Chen M, Zhang J, Li N, et al. "Promoter hypermethylation mediated downregulation of FBP2 in hepatocellular carcinoma." *Oncology Reports*, 2015;34(5):2735-2742. https://doi.org/10.3892/or.2015.4242

7. van Poelje PD, Potter SC, Chandramouli VC, et al. "Fructose-1,6-bisphosphatase inhibitors: a new class of antidiabetic agents." *Current Opinion in Drug Discovery & Development*, 2006;9(4):477-486. https://pubmed.ncbi.nlm.nih.gov/16845721/

8. Erion MD, van Poelje PD, Dang Q, et al. "MB07803, a second-generation fructose-1,6-bisphosphatase inhibitor, improves glucose homeostasis in diabetic rodents." *Journal of Pharmacology and Experimental Therapeutics*, 2005;315(3):1085-1094. https://doi.org/10.1124/jpet.105.091140

9. Gizak A, Majkowski M, Dus D, Dzugaj A. "Calcium regulates the activity of muscle fructose-1,6-bisphosphatase." *Acta Biochimica Polonica*, 2004;51(1):99-107. https://pubmed.ncbi.nlm.nih.gov/15094831/

10. Visinoni S, Khalid NF, Joannides CN, et al. "The role of liver fructose-1,6-bisphosphatase in regulating whole-body glucose homeostasis." *Journal of Biological Chemistry*, 2012;287(33):27849-27859. https://doi.org/10.1074/j